30 closest matches · ranked by relevance
Stage III Vulvar Cancer · Stage IVB Vulvar Cancer · Vulvar Squamous Cell Carcinoma
Primary: Complete Clinical and Pathologic Response — 50 Percentage of Participants
Squamous Cell Carcinoma
Primary: Response Rate — .35; .22 proportion of participants
Vulvar Cancer
Primary: Percentage of Participants With Clinical and Histologic Remission — 75 % of participants
Vulvar Intraepithelial Neoplasia (VIN)
Primary: Number of Participants With Recurrence of Dysplasia — 5; 8 Participants
Endometrial Cancer · Papillary Serous · Clear Cell Endometrial Cancer
Primary: Number of Patients With Progression-free Survival at 2 Years — 19 Participants
Head and Neck Cancer · Carcinoma, Squamous Cell · Neoplasms, Oral
Primary: Number of Patients With Solitary Elective Volume Recurrence — 0 Participants
Cervical Intraepithelial Neoplasia · Cervical Dysplasia
Primary: Incidence of Objective Response — 32; 36; 30; 0 Participants — p=0.043
Cervical Adenocarcinoma · Cervical Adenosquamous Carcinoma · Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Primary: Recurrence-free Survival (RFS) Rate at 3-years — 85.4; 88.5 percentage of participants — p=0.0927
Breast Cancer
Primary: Acute Radiation Effects (Less Than 90 Days Post Treatment) — 0 Participants
Vulvar Lichen Sclerosus
Primary: Average Scores for VLS Clinical Signs Present At Baseline, 3, 6 and 12 Months After the Last Treatment as Assessed by the Investigators — 1.85; 0.65; 0.65; 0.73 score on…
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Progression-free Survival — 25 months
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) · Vulvar Dysplasia · Vulvar Intraepithelial Neoplasia (VIN)
Primary: Percentage of Participants With No Histologic Evidence of Vulvar HSIL and No Evidence of HPV-16 and/or HPV-18 in Vulvar Tissue Samples — 15.0; 37.5 percentage of…
Recurrent Cervical Cancer · Recurrent Vaginal Cancer · Stage IB Cervical Cancer
Primary: Fasting F-18 Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) Imaging Complete Metabolic Response, Reported Following National Cancer Institute (NCI) and…
Fallopian Tube Cancer · Ovarian Cancer · Peritoneal Cavity Cancer
Primary: Overall Survival — 32 months
HPV-Related Squamous Cell Carcinoma · HNSCC
Primary: Evaluate the Tumor Shrinkage (%) to Measure the Deep Response Rate (DRR) — 25; 26; 0 Participants
Oropharyngeal Squamous Cell Cancer
Primary: Median Change in Quality of Life (QOL) From Baseline to 12 Months Post Treatment — -4.2; 0; 6.3; 10.7 score on a scale
Non Small Cell Lung Cancer
Primary: Overall Survival — 26.81; 24.97 months — p=0.831
Esophageal Cancer
Primary: Pathologic Complete Response (PCR) Rate
Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Time to Progression (TTP)
Non Small Cell Lung Cancer · Lung Cancer Stage III
Primary: 12-Month Progression-free Survival (PFS) Time — 208 days
Human Papilloma Virus Infection · Stage III Squamous Cell Carcinoma of the Oropharynx · Stage IVA Squamous Cell Carcinoma of the Oropharynx
Primary: Progression-Free Survival (PFS), Evaluated Using RECIST Version (v) 1.1 — 94.5 percentage of participants
Cervical Cancer
Primary: Disease-free Survival (Percentage of Participants Alive Without Disease) — 86.4; 82.1; 76.2; 76.9 percentage of participants — p=0.56
Breast Cancer
Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…
Cervical Squamous Cell Carcinoma · Adenosquamous Carcinoma · Adenocarcinoma
Primary: Overall Survival Rate
Oropharynx Squamous Cell Carcinoma
Primary: Progression-free Survival (PFS) — 65 percentage of patients
Epidermoid Carcinoma · Anus
Primary: Percentage of Patients With Complete Response to Treatment — 30; 10; 0; 4 Participants
Cervical Intraepithelial Neoplasia Grade 2/3 · Cervical Squamous Cell Carcinoma In Situ · Cervical Squamous Intraepithelial Neoplasia 2
Primary: Feasibility of Intravaginal Use 5-FU and Imiquimod on Alternating Weeks in Women With Biopsy Confirmed High Grade Cervical Squamous Intraepithelial Lesions. — 4; 1…
Bladder Cancer
Primary: Treatment Completion Rate — 67; 53 percentage of participants
Esophageal Carcinoma
Primary: Pathologic Complete Response — 55 participants
Cervical Cancer · Oropharyngeal Cancer · Vaginal Cancer
Primary: Number of Participants With an Objective Clinical Response — 3; 2; 2; 0 Participants